Patchell R A, Tibbs P A, Regine W F, Dempsey R J, Mohiuddin M, Kryscio R J, Markesbery W R, Foon K A, Young B
Department of Neurosurgery, University of Kentucky Medical Center, Lexington 40536-0084, USA.
JAMA. 1998 Nov 4;280(17):1485-9. doi: 10.1001/jama.280.17.1485.
For the treatment of a single metastasis to the brain, surgical resection combined with postoperative radiotherapy is more effective than treatment with radiotherapy alone. However, the efficacy of postoperative radiotherapy after complete surgical resection has not been established.
To determine if postoperative radiotherapy resulted in improved neurologic control of disease and increased survival.
Multicenter, randomized, parallel group trial.
University-affiliated cancer treatment facilities.
Ninety-five patients who had single metastases to the brain that were treated with complete surgical resections (as verified by postoperative magnetic resonance imaging) between September 1989 and November 1997 were entered into the study.
Patients were randomly assigned to treatment with postoperative whole-brain radiotherapy (radiotherapy group, 49 patients) or no further treatment (observation group, 46 patients) for the brain metastasis, with median follow-up of 48 weeks and 43 weeks, respectively.
The primary end point was recurrence of tumor in the brain; secondary end points were length of survival, cause of death, and preservation of ability to function independently.
Recurrence of tumor anywhere in the brain was less frequent in the radiotherapy group than in the observation group (9 [18%] of 49 vs 32 [70%] of 46; P<.001). Postoperative radiotherapy prevented brain recurrence at the site of the original metastasis (5 [10%] of 49 vs 21 [46%] of 46; P<.001) and at other sites in the brain (7 [14%] of 49 vs 17 [37%] of 46; P<.01). Patients in the radiotherapy group were less likely to die of neurologic causes than patients in the observation group (6 [14%] of 43 who died vs 17 [44%] of 39; P=.003). There was no significant difference between the 2 groups in overall length of survival or the length of time that patients remained functionally independent.
Patients with cancer and single metastases to the brain who receive treatment with surgical resection and postoperative radiotherapy have fewer recurrences of cancer in the brain and are less likely to die of neurologic causes than similar patients treated with surgical resection alone.
对于脑单发转移瘤的治疗,手术切除联合术后放疗比单纯放疗更有效。然而,完全手术切除后术后放疗的疗效尚未明确。
确定术后放疗是否能改善疾病的神经学控制并提高生存率。
多中心、随机、平行组试验。
大学附属癌症治疗机构。
1989年9月至1997年11月间95例脑单发转移瘤患者接受了完全手术切除(术后磁共振成像证实)并纳入研究。
患者被随机分为接受脑转移瘤术后全脑放疗(放疗组,49例患者)或不进行进一步治疗(观察组,46例患者),放疗组和观察组的中位随访时间分别为48周和43周。
主要终点是脑内肿瘤复发;次要终点是生存时间、死亡原因和独立功能能力的保留情况。
放疗组脑内任何部位的肿瘤复发均少于观察组(49例中的9例[18%]对46例中的32例[70%];P<0.001)。术后放疗可预防原转移部位(49例中的5例[10%]对46例中的21例[46%];P<0.001)及脑内其他部位(49例中的7例[14%]对46例中的17例[37%];P<0.01)的脑复发。放疗组患者死于神经学原因的可能性低于观察组(死亡的43例中的6例[14%]对39例中的17例[44%];P = 0.003)。两组在总生存时间或患者保持独立功能的时间方面无显著差异。
与仅接受手术切除治疗的类似患者相比,接受手术切除和术后放疗的脑单发转移瘤癌症患者脑内癌症复发较少,死于神经学原因的可能性也较小。